URGN
NASDAQUroGen Pharma Ltd.
Price$28.02-0.72 (-2.51%)
01:30 PM07:45 PM
News · 26 weeks41-45%
2025-12-142026-06-07
Mix2290d
- Other10(45%)
- SEC Filings5(23%)
- Insider3(14%)
- Analyst2(9%)
- Earnings2(9%)
Latest news
25 items- INSIDERChief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $142,561 worth of Ordinary Shares (5,222 units at $27.30), increasing direct ownership by 4% to 139,763 units (SEC Form 4) (for withholding tax)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- PRUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 21 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURITM (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline. Up to 102,700 ordinary shares of UroGen are issuable upon the vesting and settlement of
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Other Events8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionAgreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a settlement and license agreement (the "Agreement"') with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals, USA, Inc. (collectively, "Teva"). This Agreement resolve
- PRUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare ConferencePRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026. Goldman Sachs 47th Annual Global Healthcare Conference Date / Time:June 10, 2026, at 8:40 AM ETFormat:Fireside chat and 1x1 investor meetingsLocation:Miami Beach, FLWebcast Link:here The webcast from the conference will also be available on UroGen's corporate website, under Events & Presentations. A replay will be available for approximately 90 days. About UroGen Pharm
- INSIDERDirector Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 50% to 6,000 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SECSEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.SCHEDULE 13G - UroGen Pharma Ltd. (0001668243) (Subject)
- PRUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCPRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) durability of response (DOR) at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION t
- PRZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a 36-month duration of response (DOR) of 64.5% (95% CI, 54.6% - 72.8%) by Kaplan-Meier estimate in patients who achieved a complete response (CR) at three months (79.6%) in the pivotal Phase 3 ENVISION trial of ZUSDURI™ (mit
- INSIDERChief Medical Officer Schoenberg Mark sold $300,000 worth of Ordinary Shares (10,000 units at $30.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 134,985 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- ANALYSTLadenburg Thalmann resumed coverage on UroGen Pharma with a new price targetLadenburg Thalmann resumed coverage of UroGen Pharma with a rating of Buy and set a new price target of $43.00
- PRUroGen Pharma to Present at Upcoming Investor ConferencesPRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in May. Bank of America Health Care Conference 2026Date / Time:May 13th, at 11:15 AM ETFormat:1x1'sLocation:Las Vegas, NVWebcast Link:Here HC Wainwright 4th Annual BioConnect Investor ConferenceDate / Time:May 19th, at 10:30 AM ETFormat:1x1'sLocation:New York, NYWebcast Link:Here TD Cowen 7th Annual Oncology Innovation SummitDate / Time:May 26th, at 10:30 AM ETLocation:VirtualWebcast Link:Here The web
- SECSEC Form 10-Q filed by UroGen Pharma Ltd.10-Q - UroGen Pharma Ltd. (0001668243) (Filer)
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17th at 8:30 AM ETConference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May
- SECSEC Form DEF 14A filed by UroGen Pharma Ltd.DEF 14A - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report first quarter 2026 financial results on Wednesday, May 6th, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma Ltd. UroGen
- SECSEC Form PRE 14A filed by UroGen Pharma Ltd.PRE 14A - UroGen Pharma Ltd. (0001668243) (Filer)
- ANALYSTJefferies initiated coverage on UroGen Pharma with a new price targetJefferies initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $40.00
- PRUroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial CancerPRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its "LG-UTUC Luminaries" initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low‑grade upper tract urothelial cancer (LG‑UTUC) care. LG‑UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require rep
- PRJournal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the publication of results from the pivotal Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution in The Journal of Urology. ZUSDURI is indicated for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The publication reports a 72.2% probability
- PRUroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of RecurrenceNational survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50Many respondents report undergoing five or more cystoscopies, with some experiencing more than 15 procedures PRINCETON, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative therapies for urothelial and specialty cancers, today commended the Bladder Cancer Advocacy Network (BCAN) on its release of The New Faces of Bladder Cancer Report, a national patient-reported survey underscoring the chronic and recurrent nature of bladder cancer. The survey, which captures the experiences of mo
- PRUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 11 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDUR™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline. Up to 51,200 ordinary shares of UroGen are issuable upon the vesting and settlement of t
- SECSEC Form 10-K filed by UroGen Pharma Ltd.10-K - UroGen Pharma Ltd. (0001668243) (Filer)
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - UroGen Pharma Ltd. (0001668243) (Filer)
URGN FAQ
7 questionsWhat does UroGen Pharma Ltd. do?
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer...Where does URGN stock trade?
UroGen Pharma Ltd. (URGN) is listed on NASDAQ.What sector and industry is URGN in?
UroGen Pharma Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did UroGen Pharma Ltd. go public?
UroGen Pharma Ltd. (URGN) completed its IPO in 2017.What are analysts saying about URGN?
UroGen Pharma Ltd. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $4300.00 price target on 2026-05-11. Recent price targets range from $2300.00 to $4300.00.What companies are similar to URGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare URGN side-by-side with any of them on Quantisnow.How can I track URGN on Quantisnow?
Quantisnow aggregates UroGen Pharma Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow URGN to receive live email and push alerts on every new disclosure.